Theravance Biopharma, Inc.
TBPH
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (Jā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$16.87
Price+0.06%
$0.01
1Y
Price
Market Cap
$874.343m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-28.4%
EBITDA Margin-27.9%
Net Profit Margin+414.0%
Free Cash Flow Margin-28.4%
EBITDA Margin-27.9%
Net Profit Margin+414.0%
Free Cash Flow MarginRevenue
$109.775m
+2.2%
1y CAGR+27.1%
3y CAGR+23.3%
5y CAGREarnings
$114.541m
+8.2%
1y CAGR+97.9%
3y CAGR+46.8%
5y CAGREPS
$2.20
+6.8%
1y CAGR+90.3%
3y CAGR+72.9%
5y CAGRBook Value
$290.594m
$472.313m
Assets$181.719m
Liabilities$73.299m
DebtDebt to Assets
15.5%
0.5x
Debt to EBITDAFree Cash Flow
$268.739m
+12.7%
1y CAGR+727.4%
3y CAGR+566.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company